Clinicians are far more cautious using immunotherapy in organ transplant recipients than in patients with autoimmune disease. The risk of irreversible graft rejection is a major deterrent, reserving checkpoint inhibitors only for when no other treatment options exist.

When debating immunotherapy risks, clinicians separate manageable side effects from truly life-altering events. Hypothyroidism requiring a daily pill is deemed acceptable, whereas toxicities like diabetes or myocarditis (each ~1% risk) are viewed as major concerns that heavily weigh on the risk-benefit scale for early-stage disease.

A patient's willingness to accept immunotherapy risk depends on the transplanted organ. Kidney transplant patients may proceed, knowing dialysis is a viable backup. For heart, lung, or liver transplant patients, rejection is life-threatening, often leading them to choose hospice over treatment.

Though typically contraindicated, checkpoint inhibitors can be used for transplant recipients with advanced skin cancer. This requires shared decision-making, collaboration with the transplant team, and a specific protocol involving high-dose pulse steroids to mitigate the high risk of allograft rejection.

Unlike autologous transplant, CAR T-cell therapy does not have strict age or organ function cutoffs. Patients over 75, or with conditions like an ejection fraction of 40%, can be eligible. The key pre-treatment goal is disease stability, not a deep response, making it accessible to a wider, less fit patient population.

To mitigate organ rejection risk in transplant patients with CSCC, oncologists should coordinate with transplant teams to switch from drugs like tacrolimus to an mTOR inhibitor. This proactive switch can prevent rejection and may even enhance the immunotherapy's effectiveness.

Among solid organ transplant patients, who are already at high risk for skin cancer, heart transplant recipients are at the greatest risk. This is specifically due to the type and duration of immunosuppressive drugs required to prevent organ rejection, highlighting a critical sub-population for dermatologic surveillance.

When educating staff and patients about immunotherapies, it is helpful to distinguish between the desired effect (cytokine release killing cancer cells) and the dangerous toxicity (CRS). This reframing clarifies that CRS is an over-expression of the drug's intended mechanism, not a separate, unrelated side effect.

Using checkpoint inhibitors in renal transplant recipients requires extreme caution due to a significant risk of graft rejection, potentially leading to dialysis. This decision is a major trade-off and must involve a case-by-case discussion with the patient and a nephrologist.